PDF(Pubmed)
Abstract：
OBJECTIVE: To evaluate the clinical efficacy and systemic safety profile of conbercept in clinical practice on vascular endothelial growth factor (VEGF)-A, VEGF-B, and placental growth factor (PLGF) levels after intravitreal injections for the neovascular age-related macular degeneration (AMD).
METHODS: Thirty-five patients (35 eyes) with neovascular AMD received intravitreal injections of conbercept treatment with pro re nata protocol. Best-corrected visual acuity (BCVA) and central retinal thickness (CRT) were detected before the intravitreal injection and at 1, 3, and 12mo after conbercept treatment. The levels of serum VEGF-A, VEGF-B, and PLGF were measured by enzyme-linked immunosorbent assay before the injection and 1 and 12mo after conbercept treatments.
RESULTS: At baseline, the mean BCVA score was 39.89±14.64 letters. The mean BCVA scores were 51.03±15.78, 56.71±14.38, and 52.49±10.16 letters at 1, 3, and 12mo after conbercept treatment, and the BCVA improvements were all significant, respectively (P<0.05). At baseline, the mean CRT was 436.7±141.9 µm. At 1, 3, and 12mo after conbercept treatment, the mean CRT values were 335.1±147.8, 301.1±116.5, and 312.2±98.22 µm, and the CRT improvements were all significant, respectively (P<0.05). At baseline, 1 and 12mo after conbercept treatment, the mean levels of serum VEGF-A were 1013.8±454.3, 953.1±426.4, and 981.5±471.7 pg/mL, the mean levels of serum VEGF-B were 46.93±24.76, 42.99±19.16, and 45.32±18.76 pg/mL, the mean levels of serum PLGF at these points were 251.7±154.9, 241.3±166.7, and 245.6±147.2 pg/mL, respectively. Compared with the baseline, the levels of serum VEGF-A, VEGF-B, and PLGF did not significantly change at 1 and 12mo after conbercept treatment, respectively (P>0.05).
CONCLUSIONS: Conbercept intravitreal injection leads to BCVA and CRT improvement, however, it does not significantly affect systemic serum VEGF-A, VEGF-B, and PLGF levels at 1 and 12mo after intravitreal injection treating neovascular AMD.
METHODS: Thirty-five patients (35 eyes) with neovascular AMD received intravitreal injections of conbercept treatment with pro re nata protocol. Best-corrected visual acuity (BCVA) and central retinal thickness (CRT) were detected before the intravitreal injection and at 1, 3, and 12mo after conbercept treatment. The levels of serum VEGF-A, VEGF-B, and PLGF were measured by enzyme-linked immunosorbent assay before the injection and 1 and 12mo after conbercept treatments.
RESULTS: At baseline, the mean BCVA score was 39.89±14.64 letters. The mean BCVA scores were 51.03±15.78, 56.71±14.38, and 52.49±10.16 letters at 1, 3, and 12mo after conbercept treatment, and the BCVA improvements were all significant, respectively (P<0.05). At baseline, the mean CRT was 436.7±141.9 µm. At 1, 3, and 12mo after conbercept treatment, the mean CRT values were 335.1±147.8, 301.1±116.5, and 312.2±98.22 µm, and the CRT improvements were all significant, respectively (P<0.05). At baseline, 1 and 12mo after conbercept treatment, the mean levels of serum VEGF-A were 1013.8±454.3, 953.1±426.4, and 981.5±471.7 pg/mL, the mean levels of serum VEGF-B were 46.93±24.76, 42.99±19.16, and 45.32±18.76 pg/mL, the mean levels of serum PLGF at these points were 251.7±154.9, 241.3±166.7, and 245.6±147.2 pg/mL, respectively. Compared with the baseline, the levels of serum VEGF-A, VEGF-B, and PLGF did not significantly change at 1 and 12mo after conbercept treatment, respectively (P>0.05).
CONCLUSIONS: Conbercept intravitreal injection leads to BCVA and CRT improvement, however, it does not significantly affect systemic serum VEGF-A, VEGF-B, and PLGF levels at 1 and 12mo after intravitreal injection treating neovascular AMD.
摘要：
目的：评价康柏西普治疗血管内皮生长因子(VEGF)-A的临床疗效和全身安全性。VEGF-B,玻璃体内注射治疗新生血管性年龄相关性黄斑变性（AMD）后的胎盘生长因子（PLGF）水平。
方法：35例新生血管性AMD患者（35只眼）接受玻璃体内注射康柏西普治疗和prorenata方案。在玻璃体内注射前以及康柏西普治疗后1、3和12mo检测最佳矫正视力（BCVA）和中央视网膜厚度（CRT）。血清VEGF-A水平,VEGF-B,在注射前以及康柏西普治疗后1和12mo，通过酶联免疫吸附法测量PLGF。
结果：在基线时，平均BCVA评分为39.89±14.64个字母。康柏西普治疗后1、3和12mo的平均BCVA评分分别为51.03±15.78、56.71±14.38和52.49±10.16个字母，BCVA的改进都很重要，分别为(P<0.05)。在基线,平均CRT为436.7±141.9µm.康柏西普治疗后1、3和12mo，平均CRT值为335.1±147.8，301.1±116.5和312.2±98.22µm，CRT的改进都很重要，分别为(P<0.05)。在基线,康柏西普治疗后1和12mo，血清VEGF-A的平均水平为1013.8±454.3,953.1±426.4和981.5±471.7pg/mL,血清VEGF-B的平均水平为46.93±24.76,42.99±19.16,45.32±18.76pg/mL,这些点的血清PLGF的平均水平为251.7±154.9，241.3±166.7和245.6±147.2pg/mL，分别。与基线相比，血清VEGF-A水平,VEGF-B,PLGF在康柏西普治疗后1个月和12个月没有显着变化，分别为(P>0.05)。
结论：康柏西普玻璃体内注射可改善BCVA和CRT，然而,它不会显着影响全身血清VEGF-A，VEGF-B,玻璃体内注射治疗新生血管性AMD后1和12mo的PLGF水平。
方法：35例新生血管性AMD患者（35只眼）接受玻璃体内注射康柏西普治疗和prorenata方案。在玻璃体内注射前以及康柏西普治疗后1、3和12mo检测最佳矫正视力（BCVA）和中央视网膜厚度（CRT）。血清VEGF-A水平,VEGF-B,在注射前以及康柏西普治疗后1和12mo，通过酶联免疫吸附法测量PLGF。
结果：在基线时，平均BCVA评分为39.89±14.64个字母。康柏西普治疗后1、3和12mo的平均BCVA评分分别为51.03±15.78、56.71±14.38和52.49±10.16个字母，BCVA的改进都很重要，分别为(P<0.05)。在基线,平均CRT为436.7±141.9µm.康柏西普治疗后1、3和12mo，平均CRT值为335.1±147.8，301.1±116.5和312.2±98.22µm，CRT的改进都很重要，分别为(P<0.05)。在基线,康柏西普治疗后1和12mo，血清VEGF-A的平均水平为1013.8±454.3,953.1±426.4和981.5±471.7pg/mL,血清VEGF-B的平均水平为46.93±24.76,42.99±19.16,45.32±18.76pg/mL,这些点的血清PLGF的平均水平为251.7±154.9，241.3±166.7和245.6±147.2pg/mL，分别。与基线相比，血清VEGF-A水平,VEGF-B,PLGF在康柏西普治疗后1个月和12个月没有显着变化，分别为(P>0.05)。
结论：康柏西普玻璃体内注射可改善BCVA和CRT，然而,它不会显着影响全身血清VEGF-A，VEGF-B,玻璃体内注射治疗新生血管性AMD后1和12mo的PLGF水平。
